BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26285766)

  • 1. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
    Blakeley JO; Grossman SA; Mikkelsen T; Rosenfeld MR; Peereboom D; Nabors LB; Chi AS; Emmons G; Garcia Ribas I; Supko JG; Desideri S; Ye X
    J Neurooncol; 2015 Oct; 125(1):123-31. PubMed ID: 26285766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
    Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
    Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; BĂ©langer K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
    Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
    Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
    Kumthekar P; Grimm S; Chandler J; Mehta M; Marymont M; Levy R; Muro K; Helenowski I; McCarthy K; Fountas L; Raizer J
    J Neurooncol; 2017 Jul; 133(3):589-594. PubMed ID: 28510787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
    Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
    Grimm SA; Marymont M; Chandler JP; Muro K; Newman SB; Levy RM; Jovanovic B; McCarthy K; Raizer JJ
    J Neurooncol; 2012 Nov; 110(2):237-43. PubMed ID: 22875709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
    Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
    Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
    Gupta T; Mohanty S; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.